SCHEMBL364527

SCHEMBL364527

CS(=O)(=O)NC(=O)c1ccc(OCc2ccc(Cl)cc2)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 6/20 0.63
MRGPRX4 Q96LA9 5/20 0.61
HDAC8 Q9BY41 2/20 0.60
SCN5A Q14524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
SMPD1 P17405 1/20 0.57
HPGD P15428 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
KMT2A Q03164 1/20 0.55
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
USP2 O75604 1/20 0.50
PPARG P37231 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364759 0.93 MRGPRX4 (0.64) SCN9AMRGPRX4HDAC8SCN5AHDAC1
SCHEMBL371154 0.89 MRGPRX4 (0.62) SCN9AMRGPRX4HDAC8SCN5AHDAC1
Diethylamine SCHEMBL16239865 0.88 MRGPRX4 (0.58) SCN9AMRGPRX4HDAC8SCN5AHDAC1
SCHEMBL367120 0.85 HDAC8 (0.55) SCN9AMRGPRX4HDAC8SCN5AHDAC1
SCHEMBL16240302 0.83 MRGPRX4 (0.61) SCN9AMRGPRX4HDAC8SCN5AHDAC1
SCHEMBL365210 0.82 MAOA (0.63) SCN9ASCN5ASMN1; SMN2KMT2ARAB9A
SCHEMBL366081 0.82 MAOA (0.63) SCN9ASCN5ASMN1; SMN2KMT2ARAB9A
SCHEMBL16239862 0.81 MRGPRX4 (0.52) SCN9AMRGPRX4HDAC8SCN5AHDAC1
SCHEMBL10237079 0.81 SCN9A (0.58) SCN9AMRGPRX4SCN5A
SCHEMBL679375 0.81 SCN9A (0.58) SCN9ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 16/4885MRGPRX4 458/4885HDAC8 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.